The post-approval study data was reviewed and submitted to the FDA by Abiomed on Wednesday, March 13, 2019. The FDA has confirmed the classification of patients into two categories: Recover Right ...
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today presented updated data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results